These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31388632)

  • 21. Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus.
    Kumada T; Toyoda H; Yasuda S; Ito T; Tsuji K; Fujioka S; Hiraoka A; Kariyama K; Nouso K; Ishikawa T; Tamai T; Tada T; Tanaka J
    J Viral Hepat; 2022 Oct; 29(10):919-929. PubMed ID: 35790055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
    Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
    BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
    Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
    Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
    Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals?
    Visentini M; Fiorilli M; Casato M
    Expert Rev Hematol; 2017 Aug; 10(8):719-727. PubMed ID: 28675071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C.
    Li J; Gordon SC; Zhou Y; Boscarino JA; Schmidt MA; Daida YG; Rupp LB; Trudeau S; Lu M;
    Am J Gastroenterol; 2021 Mar; 116(3):576-583. PubMed ID: 33399360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
    Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
    Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.
    Li DK; Ren Y; Fierer DS; Rutledge S; Shaikh OS; Lo Re V; Simon T; Abou-Samra AB; Chung RT; Butt AA
    Hepatology; 2018 Jun; 67(6):2244-2253. PubMed ID: 29205416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct-acting antivirals for chronic hepatitis C.
    Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
    Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
    J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study.
    Ríos J; Sapena V; Mariño Z; Bruix J; Forns X; Morros R; Reig M; Torres F; Pontes C
    Drugs Real World Outcomes; 2024 Sep; 11(3):389-401. PubMed ID: 38874848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
    J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of TRIM22 mRNA in chronic hepatitis C patients treated with direct-acting antiviral drugs.
    Naveed M; Ali A; Sheikh N; Rafique S; Idrees M
    APMIS; 2020 Apr; 128(4):326-334. PubMed ID: 31863490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
    Backus LI; Belperio PS; Shahoumian TA; Mole LA
    Hepatology; 2018 Sep; 68(3):827-838. PubMed ID: 29377196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients.
    Nagaoki Y; Imamura M; Teraoka Y; Morio K; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Hayes CN; Chayama K; Aikata H
    Hepatol Res; 2020 Nov; 50(11):1222-1233. PubMed ID: 32767446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in the Era of Direct-Acting Antivirals for Hepatitis C in Patients with Unresectable Hepatocellular Carcinoma.
    Chen LS; Lee SW; Yang SS; Tsai HJ; Lee TY
    Dig Dis; 2022; 40(5):616-624. PubMed ID: 34753149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment.
    Imai K; Takai K; Hanai T; Suetsugu A; Shiraki M; Shimizu M
    Mol Clin Oncol; 2020 Feb; 12(2):111-116. PubMed ID: 31929880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
    Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
    J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    Toyoda H; Kumada T; Tada T; Yama T; Mizuno K
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1264-1270. PubMed ID: 29164675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals.
    Minami T; Tateishi R; Fujiwara N; Nakagomi R; Nakatsuka T; Sato M; Uchino K; Enooku K; Nakagawa H; Fujinaga H; Izumiya M; Hanajiri K; Asaoka Y; Kondo Y; Tanaka Y; Otsuka M; Ohki T; Arai M; Tanaka A; Yasuda K; Miura H; Ogata I; Kamoshida T; Inoue K; Koike Y; Akamatsu M; Mitsui H; Fujie H; Ogura K; Yoshida H; Wada T; Kurai K; Maekawa H; Obi S; Teratani T; Masaki N; Nagashima K; Ishikawa T; Kato N; Moriya K; Yotsuyanagi H; Koike K
    Liver Cancer; 2021 Jul; 10(4):309-319. PubMed ID: 34414119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.